CRISPR Medicine
mobilemenu
close
Subscribe
Home
Clinical Trials
Newsletter
Advertisement
About
search
Selfservice
|
Subscriberlogin
Logout
Prime Editors
Base Editors
Delivery
Safety
Off-target
CAR-T
Trials
Diagnostics
Missing Links
ZINC FINGER NUCLEASE (ZFN) CLINICAL TRIALS
All
|
CRISPR-Cas
|
TALEN
|
MegaNuclease
Antibacterial
Blood
Cancer
Eye
Metabolic disorder
Mucopolysaccharidosis type II, MPS II, (2018-000192-33)
Sponsors:
Sangamo Therapeutics, Inc.
Indicator
Indicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis I, MPS I, (2018-000206-28)
Sponsors:
Sangamo Therapeutics, Inc.
Indicator
Indicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis II, MPS II, (NCT03041324)
Sponsors:
Sangamo Therapeutics Inc.
Indicator
Indicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis type I, MPS I, (NCT02702115)
Sponsors:
Sangamo Therapeutics Inc.
Indicator
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine